MedPath

Gustave Roussy, Cancer Campus, Grand Paris

🇫🇷France
Ownership
Private
Employees
-
Market Cap
-
Website

Clinical Trials

227

Active:12
Completed:72

Trial Phases

5 Phases

Phase 1:33
Phase 2:75
Phase 3:55
+2 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (213 trials with phase data)• Click on a phase to view related trials

Phase 2
75 (35.2%)
Phase 3
55 (25.8%)
Not Applicable
49 (23.0%)
Phase 1
33 (15.5%)
Phase 4
1 (0.5%)

A Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction

Not Applicable
Not yet recruiting
Conditions
Leukemia, B-Cell, Chronic
Leukemia
Interventions
First Posted Date
2025-07-24
Last Posted Date
2025-07-24
Lead Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Target Recruit Count
262
Registration Number
NCT07082452
Locations
🇫🇷

Gustave Roussy, Villejuif, France

Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)

Phase 2
Recruiting
Conditions
Metastatic/Locally Advanced Small-Cell Lung Cancer
Metastatic/Locally Advanced Poorly Differentiated NEC
Metastatic/Locally Advanced High-grade MTC
Interventions
First Posted Date
2025-06-11
Last Posted Date
2025-07-16
Lead Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Target Recruit Count
40
Registration Number
NCT07016230
Locations
🇫🇷

Gustave Roussy, Villejuif, France

Analysis of Risk Factors for Hearing Loss in Survivors of Cancer Occurred During Childhood, Adolescence or Young Adulthood

Not Applicable
Not yet recruiting
Conditions
Ototoxicity, Drug-Induced
Ototoxicity, Radiation-Induced
Pediatric Cancer
First Posted Date
2025-05-04
Last Posted Date
2025-05-04
Lead Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Target Recruit Count
500
Registration Number
NCT06957132
Locations
🇫🇷

Hôpital Necker, Paris, France

🇫🇷

Institut Curie, Paris, France

🇫🇷

Gustave Roussy, Villejuif, France

Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma

Phase 4
Not yet recruiting
Conditions
Kidney Cancer
Renal Cell Cancer
Interventions
First Posted Date
2025-04-18
Last Posted Date
2025-04-18
Lead Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Target Recruit Count
50
Registration Number
NCT06934057
Locations
🇫🇷

Institut de Cancérologie de l'Ouest - Angers, Angers, France

🇫🇷

Centre Georges François Leclerc, Dijon, France

🇫🇷

Centre Léon Bérard, Lyon, France

and more 4 locations
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 46
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.